公开(公告)号：US11590218B2

公开(公告)日：2023-02-28

申请号：US16333597

申请日：2017-09-15

申请人： Baylor College of Medicine

发明人： Carlos A. Ramos ,  Cliona M. Rooney ,  Neeharika Narala

IPC分类号： A61P15/00 ,  C12N5/00 ,  A61K39/12 ,  C12N5/0783 ,  C12N5/0784 ,  A61K39/00 ,  A61P35/00

摘要： Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.

公开(公告)号：US20220409233A1

公开(公告)日：2022-12-29

申请号：US17756632

申请日：2020-11-19

申请人： Baylor College of Medicine

发明人： Stuart James Corr ,  Andrew Anderson ,  Eric Lewis ,  Brian Dawson ,  Rocky Chang Browder ,  James Sulburk

IPC分类号： A61B17/34 ,  A61B8/00 ,  A61B8/08

摘要： Embodiments of the disclosure include a tissue and/or access device that allows for adjustability of placement of a needle for accessing a blood vessel of an individual in need thereof, particularly when used with an imaging device. The adjustability originates from both angle of the needle for insertion into the body of the individual and longitudinal placement of the needle on the body of the individual. In specific embodiments, a needle guide through which the needle traverses is detachable.

公开(公告)号：US20220387530A1

公开(公告)日：2022-12-08

申请号：US17775203

申请日：2019-11-07

申请人： Baylor College of Medicine

发明人： Masataka Suzuki ,  Amanda Rosewell Shaw ,  Caroline Elaine Porter ,  Norihiro Watanabe ,  Malcolm K. Brenner ,  Andrew Sikora

IPC分类号： A61K35/768 ,  A61P35/00 ,  A61K38/20 ,  A61K39/395 ,  A61K35/17 ,  C07K14/005 ,  A61K38/17

摘要： The present disclosure concerns combination therapy for cancer thatutilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.

公开(公告)号：US20220362219A1

公开(公告)日：2022-11-17

申请号：US17757058

申请日：2020-12-11

申请人： Baylor College of Medicine

发明人： Rui Chen

IPC分类号： A61K31/423 ,  A61K31/4155 ,  A61K31/122 ,  A61K31/60 ,  A61K31/426 ,  A61K31/12 ,  A61K31/365 ,  A61K31/519 ,  A61K31/437 ,  A61K31/515 ,  A61P27/02

摘要： Embodiments of the disclosure encompass methods and compositions for the treatment of medical conditions in which cell regeneration is in need, including neural cells. In specific embodiments, the cell are retinal cells and include Müller glial cells. In particular embodiments, an individual with retinal regeneration is provided an effective amount of one or more histone acetylase inhibitors for the purpose of regenerating retinal cells, including retinal neurons.

公开(公告)号：US20220348963A1

公开(公告)日：2022-11-03

申请号：US17855322

申请日：2022-06-30

申请人： Baylor College of Medicine

发明人： Brendan Lee ,  Kilian Guse ,  Zhechao Ruan

IPC分类号： C12N15/86 ,  C07K14/545 ,  C12N7/00

摘要： The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-I receptor antagonist (IL-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-I receptor antagonist (IL-I Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-I receptor antagonist (IL-I Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.

公开(公告)号：US20220326241A1

公开(公告)日：2022-10-13

申请号：US17634218

申请日：2020-08-12

申请人： Baylor College of Medicine ,  The Broad Institute, Inc. ,  The General Hospital Corporation

发明人： Matthew J. Ellis ,  Bing Zhang ,  Eric Jaehnig ,  Steven Carr ,  Shankha Satpathy ,  Michael Gillette

IPC分类号： G01N33/574 ,  C12Q1/6886 ,  G01N33/68

摘要： Methods disclosed herein concern cancer proteogenomics, which integrates genomics, transcriptomics and mass spectrometry (MS)-based proteomics to gain insights into cancer biology and treatment efficacy. To promote clinical utility of embodiments herein, proteogenomics approaches were developed for frozen core needle biopsies using tissue-sparing specimen processing with or without a microscaled proteomics workflow.

公开(公告)号：US20220290224A1

公开(公告)日：2022-09-15

申请号：US17669211

申请日：2022-02-10

申请人： THE BROAD INSTITUTE, INC. ,  BAYLOR COLLEGE OF MEDICINE

发明人： Erez LIEBERMAN AIDEN ,  Suhas RAO ,  Elena STAMENOVA ,  Olga DUDCHENKO ,  Eric LANDER

IPC分类号： C12Q1/6869 ,  C12Q1/6806 ,  C40B30/04

摘要： Disclosed is an in situ method for detecting spatial proximity relationships between nucleic acid sequences, such as DNA, in a cell. The method includes: providing a sample of one or more cells comprising nucleic acids; fragmenting the nucleic acids present in the cells that leaves 5′ overhanging ends; filling in the overhanging ends with at least one labeled nucleotide; joining the filled in end of the fragmented nucleic acids that are in close physical proximity to create one or more end joined nucleic acid fragments having a junction; isolating the one or more end joined nucleic acid fragments using the labeled nucleotide; and determining the sequence at the junction of the one or more end joined nucleic acid fragments.

公开(公告)号：US11376332B2

公开(公告)日：2022-07-05

申请号：US16341412

申请日：2017-04-07

申请人： Baylor College of Medicine

发明人： Nabil M. Ahmed ,  Hebatalla S. Samaha ,  Antonella Pignata ,  Kristen Fousek

IPC分类号： A61K47/64 ,  C07K14/705 ,  A61K39/38 ,  A61K39/39 ,  A61K48/00 ,  A61P31/10 ,  A61P5/00 ,  A61P35/00 ,  A61K35/17 ,  A61K35/28

摘要： Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods employ targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic, diagnostic or interventional moiety to be delivered. In specific cases, the ALCAM-binding moiety is present on or with the therapeutic moiety in multiple iterations. In certain embodiments, the ALCAM-binding moiety comprises at least one SRCR domain from CD6 and a stalk, such as from CD6, of the secretable or molecular form thereof.

公开(公告)号：US20220196697A1

公开(公告)日：2022-06-23

申请号：US17383981

申请日：2021-07-23

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  BAYLOR COLLEGE OF MEDICINE

发明人： Livia SCHIAVINATO EBERLIN ,  Thomas MILNER ,  Jialing ZHANG ,  Noah GIESE ,  John LIN ,  Jeffrey R. KUHN ,  James SULIBURK ,  Nitesh KATTA

IPC分类号： G01N35/10 ,  A61B10/04 ,  H01J49/04 ,  A61B10/00 ,  A61B10/02

摘要： Methods and apparatus are provided for cleaning or exchanging medical devices. Certain embodiments may include a cassette comprising a plurality of medical devices, where the orientation of the cassette can be changed while the cassette is coupled to a processing instrument.

公开(公告)号：US20220195025A1

公开(公告)日：2022-06-23

申请号：US17547069

申请日：2021-12-09

申请人： GENZYME CORPORATION ,  Baylor College of Medicine

发明人： Brendan Lee ,  Kuber T. Sampath

IPC分类号： C07K16/22 ,  A61K39/395 ,  A61K33/42 ,  A61K45/06

摘要： The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).